Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.

Spread the love

. 2021;1297:27-42.

doi: 10.1007/978-3-030-61663-2_3.

Affiliations

Item in Clipboard

Marta Vázquez et al. Adv Exp Med Biol. 2021.

Abstract

Over the past few years, considerable attention has focused on cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), the two major constituents of Cannabis sativa, mainly due to the promising potential medical uses they have shown. However, more information on the fate of these cannabinoids in human subjects is still needed and there is limited research on the pharmacokinetic drug-drug interactions that can occur in the clinical setting and their prevalence. As the use of cannabinoids is substantially increasing for many indications and they are not the first-line therapy in any treatment, health care professionals must be aware of drug-drug interactions during their use as serious adverse events can happen related with toxic or ineffective outcomes. The present chapter overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD and THC in humans and discusses relevant drug-drug interactions, giving a plausible explanation to facilitate further research in the area.

Keywords: Cannabidiol; Drug-drug interactions; Pharmacokinetics; Δ9-tetrahydrocannabinol.

References

    1. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz ML (2007) Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 82(5):572–578 – PubMed DOI PMC
    1. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38(1):21–43 – PubMed PMC
    1. Agurell S, Leander K (1971) Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 8(4):391–402 – PubMed PMC
    1. Aizpurua-Olaizola O, Soydaner U, Ozturk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A (2016) Evolution of the cannabinoid and Terpene content during the growth of Cannabis sativa plants from different Chemotypes. J Nat Prod 79(2):324–331 – PubMed DOI PMC
    1. Al Saabi A, Allorge D, Sauvage FL, Tournel G, Gaulier JM, Marquet P, Picard N (2013) Involvement of UDPglucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos 41(3):568–574 – PubMed DOI PMC

Avatar

Schaka

error: Content is protected !!
%d blogueurs aiment cette page :